Literature DB >> 19052918

Short or long survival in multiple myeloma. A simple method for determining the prognosis.

Judit Várkonyi1, Edina Bajzik, Adám Fazakas, Sándor Sipka, István Karádi.   

Abstract

Finding prognostic factors in multiple myeloma is a real challenge. Several attempts might be found in the literature for that purpose but the results are not satisfactory. Therefore, in the current retorpective study authors analyzed the potential prognostic value of some laboratory data in 104 patients with multiple myeloma. They found the albumin and M-component ratio being lower than 1 and the initial WBC <4,5 x 10(9)/l correlated strongly with poor prognosis. In addition the low albumin level was not related to albuminuria and that the low WBC was not linked to bone marrow infiltration rate or to antineutrophil antibody formation. On the basis of their experiences authors created an AMWBC score containing A/M and WBC at diagnosis found to be in good correlation to prognosis. Further studies involving more patients are needed to verify the real prognostic value of AMWBC score in multiple myeloma treated with new targeted therapies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19052918     DOI: 10.1007/s12253-008-9134-9

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  15 in total

Review 1.  Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty.

Authors:  W B Ershler; E T Keller
Journal:  Annu Rev Med       Date:  2000       Impact factor: 13.739

2.  The antigen/receptor specificity of antigranulocyte antibodies in patients with SLE.

Authors:  A Sipos; C Csortos; S Sipka; P Gergely; I Sonkoly; G Szegedi
Journal:  Immunol Lett       Date:  1988-12       Impact factor: 3.685

3.  Immunofluorescent plasma cell labeling indices (LI) using a monoclonal antibody (BU-1).

Authors:  P R Greipp; T E Witzig; N J Gonchoroff
Journal:  Am J Hematol       Date:  1985-11       Impact factor: 10.047

4.  Long-term survival in multiple myeloma.

Authors:  R A Kyle
Journal:  N Engl J Med       Date:  1983-02-10       Impact factor: 91.245

5.  International staging system for multiple myeloma.

Authors:  Philip R Greipp; Jesus San Miguel; Brian G M Durie; John J Crowley; Bart Barlogie; Joan Bladé; Mario Boccadoro; J Anthony Child; Herve Avet-Loiseau; Jean-Luc Harousseau; Robert A Kyle; Juan J Lahuerta; Heinz Ludwig; Gareth Morgan; Raymond Powles; Kazuyuki Shimizu; Chaim Shustik; Pieter Sonneveld; Patrizia Tosi; Ingemar Turesson; Jan Westin
Journal:  J Clin Oncol       Date:  2005-04-04       Impact factor: 44.544

6.  [The significance of myelodysplasia in untreated patients with multiple myeloma].

Authors:  M Mori; T Abe; T Takei; K Shibata
Journal:  Rinsho Ketsueki       Date:  1992-05

7.  A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience.

Authors:  Joth L Jacobson; Mohamad A Hussein; Bart Barlogie; Brian G M Durie; John J Crowley
Journal:  Br J Haematol       Date:  2003-08       Impact factor: 6.998

8.  Review of 1027 patients with newly diagnosed multiple myeloma.

Authors:  Robert A Kyle; Morie A Gertz; Thomas E Witzig; John A Lust; Martha Q Lacy; Angela Dispenzieri; Rafael Fonseca; S Vincent Rajkumar; Janice R Offord; Dirk R Larson; Matthew E Plevak; Terry M Therneau; Philip R Greipp
Journal:  Mayo Clin Proc       Date:  2003-01       Impact factor: 7.616

9.  Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma.

Authors:  Athanasios B-T Fassas; Tray Spencer; Jeffrey Sawyer; Maurizio Zangari; Choon-Kee Lee; Elias Anaissie; Firas Muwalla; Christopher Morris; Bart Barlogie; Guido Tricot
Journal:  Br J Haematol       Date:  2002-09       Impact factor: 6.998

10.  An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma.

Authors:  I Hus; A Dmoszynska; J Manko; M Hus; D Jawniak; M Soroka-Wojtaszko; A Hellmann; H Ciepluch; A Skotnicki; T Wolska-Smolen; K Sulek; T Robak; L Konopka; J Kloczko
Journal:  Br J Cancer       Date:  2004-11-29       Impact factor: 7.640

View more
  2 in total

1.  The albumin and monoclonal protein ratio as prognostic marker for multiple myeloma in the era of novel agents.

Authors:  Katalin Kádár; Krisztina Wolf; Judit Tábori; István Karádi; Judit Várkonyi
Journal:  Pathol Oncol Res       Date:  2012-07       Impact factor: 3.201

2.  High density of tryptase-positive mast cells in patients with multiple myeloma: correlation with parameters of disease activity.

Authors:  Maria Devetzoglou; Rodanthi Vyzoukaki; Maria Kokonozaki; Athina Xekalou; Constantina A Pappa; Anastasia Papadopoulou; Athanasios Alegakis; Nikolaos Androulakis; Michael G Alexandrakis
Journal:  Tumour Biol       Date:  2015-05-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.